

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)



(10) International Publication Number
WO 2024/240241 A2

(51) International Patent Classification:

C07D 213/78 (2006.01)	C07D 471/04 (2006.01)
C07D 231/14 (2006.01)	C07D 471/08 (2006.01)
C07D 277/56 (2006.01)	C07D 487/04 (2006.01)
C07D 401/06 (2006.01)	C07D 491/08 (2006.01)
C07D 401/12 (2006.01)	A61P 35/00 (2006.01)
C07D 401/14 (2006.01)	A61P 35/04 (2006.01)
C07D 405/06 (2006.01)	A61K 31/444 (2006.01)
C07D 405/14 (2006.01)	A61K 31/4439 (2006.01)
C07D 407/12 (2006.01)	A61K 31/427 (2006.01)
C07D 409/12 (2006.01)	A61K 31/4188 (2006.01)
C07D 417/14 (2006.01)	A61K 31/404 (2006.01)
C07D 451/02 (2006.01)	A61K 31/4184 (2006.01)
C07D 453/02 (2006.01)	

(21) International Application Number:

PCT/CN2024/095073

(22) International Filing Date:

24 May 2024 (24.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/096312	
25 May 2023 (25.05.2023)	CN
PCT/CN2024/073002	
18 January 2024 (18.01.2024)	CN
PCT/CN2024/091147	
06 May 2024 (06.05.2024)	CN

(71) Applicant: **ALLORION THERAPEUTICS INC**
[US/US]; 22 Strathmore Road, Natick, MA 0176 (US).

(72) Inventor; and

(71) Applicant (for UG only): **CHENG, Dai** [US/CN]; Room 901, Bldg 2, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Guangzhou, Guangdong 510530 (CN).

(72) Inventors: **YU, Ming**; 22 Strathmore Road, Natick, MA 0176 (US). **LU, Yipin**; 22 Strathmore Road, Natick, MA 0176 (US). **LI, Fang**; 22 Strathmore Road, Natick, MA 0176 (US). **GU, Lina**; 22 Strathmore Road, Natick, MA 0176 (US). **WANG, Tiansheng**; 22 Strathmore Road, Natick, MA 0176 (US).

(74) Agent: **SINO-CREATIVITY INTELLECTUAL PROPERTY LAW FIRM**; Room 23A03, Block 4, the Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing 100020 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: EGFR INHIBITORS AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are compounds having an amide-based backbone that is connected to multiple ring structures, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions thereof, and method of use thereof as selective allosteric inhibitors of EGFR mutants.

WO 2024/240241 A2